Paratek Pharmaceuticals Inc (NASDAQ:PRTK) – Investment analysts at G.Research cut their FY2024 EPS estimates for Paratek Pharmaceuticals in a report issued on Thursday, June 25th. G.Research analyst K. Kedra now forecasts that the specialty pharmaceutical company will post earnings per share of $0.90 for the year, down from their prior estimate of $0.95.
Other analysts have also issued research reports about the stock. ValuEngine upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Wedbush restated an “outperform” rating on shares of Paratek Pharmaceuticals in a research report on Monday, March 9th. Finally, Zacks Investment Research raised Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a report on Tuesday, June 23rd. Eight analysts have rated the stock with a buy rating, Paratek Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $15.90.
NASDAQ:PRTK opened at $5.22 on Monday. The company has a 50 day moving average price of $4.59 and a 200-day moving average price of $4.03. Paratek Pharmaceuticals has a 1-year low of $2.50 and a 1-year high of $5.89. The firm has a market cap of $222.98 million, a price-to-earnings ratio of -1.50 and a beta of 1.54.
Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Monday, May 11th. The specialty pharmaceutical company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.14. Paratek Pharmaceuticals had a negative return on equity of 5,327.73% and a negative net margin of 528.28%. The company had revenue of $7.92 million during the quarter, compared to analysts’ expectations of $7.75 million.
In other Paratek Pharmaceuticals news, insider Randall B. Brenner sold 6,198 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $4.75, for a total transaction of $29,440.50. Following the completion of the transaction, the insider now owns 130,813 shares of the company’s stock, valued at $621,361.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Evan Loh sold 9,595 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $4.75, for a total value of $45,576.25. Following the completion of the transaction, the chief executive officer now owns 552,008 shares in the company, valued at approximately $2,622,038. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,709 shares of company stock worth $154,510. Company insiders own 8.30% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in PRTK. BlackRock Inc. grew its holdings in shares of Paratek Pharmaceuticals by 3.7% during the first quarter. BlackRock Inc. now owns 2,408,849 shares of the specialty pharmaceutical company’s stock worth $7,588,000 after buying an additional 84,937 shares in the last quarter. Rock Springs Capital Management LP boosted its position in Paratek Pharmaceuticals by 307.0% during the first quarter. Rock Springs Capital Management LP now owns 1,526,310 shares of the specialty pharmaceutical company’s stock worth $4,808,000 after acquiring an additional 1,151,310 shares during the last quarter. General American Investors Co. Inc. grew its stake in Paratek Pharmaceuticals by 24.7% during the 1st quarter. General American Investors Co. Inc. now owns 803,184 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after acquiring an additional 158,861 shares in the last quarter. State Street Corp raised its holdings in Paratek Pharmaceuticals by 0.8% in the 4th quarter. State Street Corp now owns 679,099 shares of the specialty pharmaceutical company’s stock valued at $2,737,000 after acquiring an additional 5,320 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Paratek Pharmaceuticals by 157.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 341,322 shares of the specialty pharmaceutical company’s stock worth $1,376,000 after purchasing an additional 208,755 shares in the last quarter. 43.41% of the stock is currently owned by institutional investors.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.
Further Reading: Call Option Volume
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.